Labcorp Expands PathAI Pact to Roll Out Digital Pathology Platform in US

Why It Matters

Scaling AI‑powered digital pathology lets Labcorp deliver faster, more accurate diagnoses, bolstering its market position and accelerating AI adoption across clinical laboratories.

Key Takeaways

• Labcorp rolls out PathAI AISight Dx across U.S.
• AI platform improves slide review turnaround times.
• FDA 510(k) clearance enables rapid feature updates.
• Quest Diagnostics also partnered with PathAI this year.
• Digital pathology expands AI integration in clinical labs.

Pulse Analysis

The digital pathology market is entering a rapid growth phase as AI tools transform how tissue samples are evaluated. Scanned slide images combined with machine‑learning algorithms can highlight diagnostic features, reduce human error, and streamline case management. Hospitals and reference labs are increasingly adopting these platforms to meet rising demand for faster results, especially in oncology and infectious disease testing, where timely decisions directly impact patient outcomes.

Labcorp’s renewed collaboration with PathAI builds on a 2019 investment and a 2021 clinical‑trial integration, now extending AISight Dx to its nationwide network. By leveraging FDA‑cleared AI for image analysis, secure cloud storage, and seamless workflow connectivity, Labcorp aims to cut diagnostic latency and standardize reporting across its 70+ labs. This strategy directly counters Quest Diagnostics’ parallel AI rollout, intensifying competition among the two largest U.S. testing giants and prompting further consolidation of AI capabilities in the diagnostic sector.

Regulatory clarity, exemplified by PathAI’s 2025 510(k) amendment, eases the rollout of new scanners, file formats, and display options without additional FDA submissions, accelerating innovation cycles. As AI becomes embedded in pathology, clinicians can expect more consistent diagnoses, virtual staining techniques, and predictive insights that inform treatment plans. The broader implication is a shift toward data‑driven pathology, where AI augments human expertise, improves operational efficiency, and ultimately enhances patient care across the healthcare continuum.